Tompkins Christine M, Zareba Wojciech, Greenberg Henry, Goldstein Robert, McNitt Scott, Polonsky Bronislava, Brown Mary, Kutyifa Valentina
Emory University School of Medicine, Atlanta, Georgia.
University of Rochester Medical Center, Rochester, New York.
Heart Rhythm. 2023 Jan;20(1):39-45. doi: 10.1016/j.hrthm.2022.08.018. Epub 2022 Aug 22.
Studies have reported sex differences in outcomes following implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy-defibrillator (CRT-D) implantation. However, little is known about sex differences with regard to mode of death or device efficacy following ICD or CRT-D implantation.
The purpose of this study was to investigate whether sex influenced mode of death or device efficacy in ICD and CRT-D subjects enrolled in the MADIT (Multicenter Automatic Defibrillator Implantation Trial) studies (MADIT-II, MADIT-CRT, and MADIT-RIT).
The combined MADIT cohort consisted of 3038 men and 1000 women with ischemic cardiomyopathy (ICM) or nonischemic cardiomyopathy (NICM), left ventricular ejection fraction ≤30%; New York Heart Association functional class I-III heart failure who received ICD or CRT-D. Mode of death was divided into cardiac and noncardiac causes, reviewed by independent adjudication committees.
A total of 295 men and 66 women died (9.7% vs 6.6%; P =.003) during 26 months. The most common cause of death was nonarrhythmic cardiac death in men (n = 121 [41%]) and noncardiac death in women (n = 22 [33%]). All-cause mortality and cardiac deaths were 1.5- to 2.0-fold higher in men vs women with ICM but similar for those with NICM after adjustment for covariates. ICD efficacy was similar in men and women, resulting in a 50% reduction in all-cause mortality. CRT-D was more effective at reducing all-cause and cardiac death in women than men.
Mode of death differs between sex and is dependent on the underlying cardiac substrate. Compared to women, cardiac death is higher in men with ICM but similar in those with NICM. ICDs are equally effective at reducing mortality in both men and women. However, CRT-D may be more effective at reducing mortality in women.
研究报告了植入式心脏复律除颤器(ICD)和心脏再同步化治疗除颤器(CRT-D)植入后结局存在性别差异。然而,关于ICD或CRT-D植入后的死亡方式或设备疗效方面的性别差异知之甚少。
本研究的目的是调查性别是否会影响参加MADIT(多中心自动除颤器植入试验)研究(MADIT-II、MADIT-CRT和MADIT-RIT)的ICD和CRT-D受试者的死亡方式或设备疗效。
合并的MADIT队列包括3038名男性和1000名女性,患有缺血性心肌病(ICM)或非缺血性心肌病(NICM),左心室射血分数≤30%;纽约心脏协会心功能I-III级心力衰竭,接受了ICD或CRT-D。死亡方式分为心脏原因和非心脏原因,由独立的判定委员会进行审查。
在26个月期间,共有295名男性和66名女性死亡(9.7%对6.6%;P = 0.003)。男性最常见的死亡原因是非心律失常性心脏死亡(n = 121 [41%]),女性最常见的死亡原因是非心脏死亡(n = 22 [33%])。调整协变量后,ICM男性的全因死亡率和心脏死亡率比女性高1.5至2.倍,但NICM患者的情况相似。ICD在男性和女性中的疗效相似,全因死亡率降低了50%。CRT-D在降低女性全因死亡率和心脏死亡率方面比男性更有效。
死亡方式存在性别差异,且取决于潜在的心脏基质。与女性相比,ICM男性的心脏死亡率更高,但NICM患者相似。ICD在降低男性和女性死亡率方面同样有效。然而,CRT-D在降低女性死亡率方面可能更有效。